Apramycin (TP-6076)

About Innoviva

Innoviva operates a distinctive hybrid business model, leveraging long-term royalty streams from partnered respiratory drugs like TRELEGY and ANORO to fund strategic R&D and acquisitions. The company has successfully transitioned from its origins as Theravance into a financially robust entity with a $1.69B market cap, using its cash generation to build a promising pipeline in oncology and anti-infectives. Its strategy focuses on disciplined capital allocation, targeting late-stage or commercial assets to drive future growth while maintaining a strong balance sheet.

Therapeutic Areas